Biological therapies in Crohn’s disease

Patryk Kaczor, Katarzyna Lipa, Magdalena Julia Jabłońska, Kamil Leis, Krystian Kałużny, Przemysław Gałązka


Crohn’s disease is one of the chronic inflammatory diseases of the digestive tract. Pathophysiology of this disease involves the genetic and environmental factors, but the most important causative factor is anti-inflammatory reaction of the organism, which eventually leads to inflammatory changes, fibrosis and necrosis. Glucocorticosteroids are commonly used in therapy and may cause many negative side effects. Nowadays, new biological medicines are being tested, which are supposed to be an alternative method of treating Crohn’s disease. Infliximab, adalimumab, certolizumab pegol, natalizumab, etanerecept, vedolizumab and ustekinumab are the examples of those drugs, on which the research was already carried out. They lead to healing of the mucous membrane of the digestive tract, and thus to remission of the disease.


Crohn’s disease; chronic inflammatory disease; biological therapy

Full Text:



Freeman HJ: Natural history and long-term clinical course of Crohn’s disease. World Journal of Gastroenterology 20(1), 31-36 (2014)

Wegner A, Szychta M, Kierkuś J: Rola terapii biologicznej w podtrzymaniu remisji u dzieci z chorobą Leśniowskiego i Crohna, Pediatria Polska 88(2), 131-137 (2013)

Wasilewska A, Marciniak R, Drews M: Leśniowski-Crohn Disease - Historical Overview, Polish Journal of Surgery 81(7), 329-336 (2009)

Lichtarowicz AM, Mayberry JF: Antoni Lésniowski and his contribution to regional enteritis (Crohn’s disease), Journal of the Royal Society of Medicine 81(8), 468-470 (1988)

Baumgart DC, Sandborn WJ: Crohn's disease, The Lancet 380, 1590 - 1605 (2012)

Derkacz A, Olczyk P, Komosinska-Vassev K: Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases, Disease Markers (2018)

Cho JH, Brant SR: Recent Insights Into the Genetics of Inflammatory Bowel Disease, Gastroenterology 140(6), 1704-1712 (2011)

Hanauer SB et al.: Human anti–tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I Trial, Gastroenterology 130(2), 323-333 (2006)

Nuti F et al.: Biological therapy in a paediatric Crohn’s disease population at a referral center, Journal of paediatric gastroenterology and nutrition 58(5), 582-587 (2014)

Sandborn WJ et al.: Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial, Gastroenterology 121(5), 1088-1094 (2001)

Present DH et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease, New England Journal of Medicine 340(18), 1398-1405 (1999)

Sorrentino D et al: Low dose infliximab for prevention of postoperative recurrence of Crohn’s disease: long term follow-up and impact of infliximab trough levels and antibodies to infliximab, Public Library of Science 10(12) (2015)

Sandborn WJ et al.: Certolizumab pegol for the treatment of Crohn's disease, New England Journal of Medicine 357(3), 228-238 (2007)

Sandborn WJ et al.: Natalizumab induction and maintenance therapy for Crohn's disease, New England Journal of Medicine 353(18), 1912-1925 (2005)

Sandborn WJ et al.: Vedolizumab as induction and maintenance therapy for Crohn's disease, New England Journal of Medicine 369(8), 711-721 (2013)

Bishop C et al.: Ustekinumab in paediatric Crohn’s disease patients, Journal of paediatric gastroenterology and nutrition 63(3), 348-351 (2016)



  • There are currently no refbacks.

Copyright (c) 2018 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski